Introducing our Advanced, Patented Equine Plasma Technology, the AlphaActive™ Concentrate Process

Alpha2EQ® is the only orthobiologic device that is proven to isolate and concentrate α2M from plasma, intensifying the all-natural healing proteins of the horse’s own blood. The α2M molecule has proven success in decreasing inflammation, relieving pain and modulating cartilage degeneration that is the result of osteoarthritis.
null
Provides the highest level of concentration of α2M in plasma available on the market today — up to five times more than naturally occurring levels
null
Only autologous process that concentrates α2M for mammals to obtain a U.S. patent
null
Attending veterinarian can process and treat in just one hour with an uncomplicated three-step, minimally invasive procedure
null
Multi-dose kit allows veterinarianss to inject multiple sites in the same treatment
null
Excess α2M from the injectate bag can be frozen for future treatments
null
Drug free and has no competition restrictions and no banned substances. Always follow your organization’s rules for general joint injections
Among equine joint diseases with the greatest impact and clinical relevance in orthopedics, OA remains the most devastating. The condition is often associated with poor performance, early retirement and a significant financial burden for owners of affected athletes (McIlwaraith, 2012).

Understanding the research that has been done, Astaria Global developed the AlphaActive process, a highly improved process leveraging PRP methodology derivative of Platelet Poor Plasma (PPP) that concentrates plasma proteins from the equine patient’s own blood. Alpha2EQ is powered by the advanced, patented AlphaActive Concentrate Process.

McIlwraith, C. W., Frisbie, D. D., & Kawcak, C. E. (2012, November 1). The horse as a model of naturally occurring osteoarthritis. Retrieved November 7, 2019, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626203/.

For more information contact the Astaria Global team.